DFMO for rare childhood cancers
Part of Cancer clinical trials.
This trial studies a drug called DFMO for children and young adults with certain rare cancers that have not responded to standard treatments or have come back. DFMO may help stop cancer cells from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a high-risk childhood cancer like neuroblastoma, medulloblastoma, or a rare tumor with certain genetic changes.
- You are between 0 and 30 years old at the time of your first diagnosis.
- You have finished standard treatments for your cancer.
- You cannot join if you are currently taking another experimental drug.
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving fewer chemotherapy drugs along with other targeted therapies (monoclonal antibodies) works well for children with high-risk neuroblastoma. It aims to reduce side effects while still treating the cancer effectively.
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
This trial tests a combination of two drugs (eflornithine and AMXT 1501) for children and young adults with certain types of cancer that have relapsed or not responded to standard treatment, or for a specific brain tumor (DIPG) at diagnosis. The goal is to see if this drug pair is safe and effective.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a personalized treatment plan for children with high-risk neuroblastoma, a type of nerve tissue cancer. It aims to improve outcomes by tailoring therapy based on each child's tumor characteristics and response to prior treatment.
This study tests a combination of two drugs, MM-398 and cyclophosphamide, for children and young adults whose cancer has come back or not responded to earlier treatment. The goal is to find the best dose and see how well it works against certain tumor types.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.